Azupedia

Talk:Immunoglobulin therapy

Revision as of 17:04, 3 January 2023 by imported>Fire (Created page with "{{Infobox drug | drug_name = | INN = | type = <!-- empty --> | image = | width = | alt = | caption = <!-- Clinical data --> | pronounce = | tradename = Flebogamma, Gammagard, Hizentra, others | Drugs.com = {{Drugs.com|monograph|immune-globulin}} | MedlinePlus = | licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) -->...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Immunoglobulin therapy
Clinical data
Trade namesFlebogamma, Gammagard, Hizentra, others
Other namesnormal human immunoglobulin (HNIG), human normal immunoglobulin (HNIG)
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		Intravenous, intramuscular, subcutaneous
ATC code
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
UNII
  1. ↑ 1.0 1.1 "Xembify APMDS". Therapeutic Goods Administration (TGA). 15 July 2022. Archived from the original on 14 July 2022. Retrieved 17 July 2022.
  2. ↑ "Regulatory Decision Summary - Xembify". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
  3. ↑ "Summary Basis of Decision - HyQvia". Health Canada. 23 October 2014. Retrieved 6 August 2022.
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Talk:Immunoglobulin_therapy&oldid=3091"
Return to "Immunoglobulin therapy" page.